undamentalytics Newsletter

Buchan Jane: insider trades

Director at 2 companies we cover. 1 open-market purchase and 10 sales not made under a pre-set plan, reported from August 21, 2012 to December 13, 2023.

Would copying Buchan Jane’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. After their sales, the shares moved +2.8% against the index over 12 months on average (a negative figure means selling was the right call); 40% trailed it. None of their purchases could be priced, so there is no copy portfolio.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Buchan Jane: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 10 −2.7% −0.6% 50% 7 −1.10 0.31 No reliable evidence
Sales, 12 months after the report 10 +2.8% +7.6% 40% 7 0.49 0.64 No reliable evidence
Sales, 12 months after the trade 10 +1.5% +5.6% 50% 7 0.29 0.78 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Globe Life GL —010August 21, 2012December 13, 2023
Immix Biopharma, Inc. IMMX —10September 11, 2023September 11, 2023

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
December 13, 2023December 12, 2023 GL Sale $124,500 −14.2%−42.4%−47.3%
September 11, 2023September 7, 2023 IMMX Purchase $49,200 not yetnot yetnot yet
March 16, 2023March 16, 2023 GL Sale $201,305 −10.1%−21.0%−23.8%
November 4, 2021November 2, 2021 GL Sale $156,536 +13.9%+38.3%+40.7%
June 3, 2021June 2, 2021 GL Sale $1,235,419 −18.4%−7.1%−6.2%
November 14, 2016November 14, 2016 GL Sale $272,034 +2.7%+3.1%−0.2%
December 11, 2015December 11, 2015 GL Sale $270,342 −4.6%+14.8%+11.6%
December 3, 2014December 1, 2014 GL Sale $357,327 +0.5%+12.2%+11.4%
November 26, 2013November 25, 2013 GL Sale $387,179 −1.6%−10.1%−8.8%
December 4, 2012December 3, 2012 GL Sale $335,209 +2.3%+18.2%+16.9%
August 21, 2012August 16, 2012 GL Sale $312,955 +2.6%+22.5%+20.7%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Buchan Jane traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.